NASDAQ:SGP Spyglass Pharma Q1 2026 Earnings Results & Report $24.92 +0.30 (+1.22%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$25.11 +0.19 (+0.76%) As of 10/9/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Spyglass Pharma missed analyst earnings expectations in its Q1 2026 results, released May 14, 2026. The company reported EPS of -$0.69 versus the -$0.67 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2026Report DateMay 14, 2026TimeAfter Market ClosesConference Call4:00 PM ET Spyglass Pharma EPS ResultsActual EPS-$0.69Consensus EPS -$0.67Beat/MissMissed by -$0.02One Year Ago EPSN/ASpyglass Pharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Spyglass Pharma Q1 2026 Earnings FAQ Did Spyglass Pharma beat earnings estimates for Q1 2026? Spyglass Pharma (NASDAQ:SGP) reported earnings of -$0.69 per share for Q1 2026, missing the consensus estimate of -$0.67. The report was announced on Thursday, May 14, 2026. Spyglass Pharma Earnings HeadlinesSpyGlass Pharma closes AVS buy for $13 millionOctober 4, 2026 | americanbankingnews.comWall Street Zen Downgrades Spyglass Pharma (NASDAQ:SGP) to SellOctober 3, 2026 | americanbankingnews.comElon just declared war on your phoneSpaceX reportedly agreed to pay 8 billion dollars for a major slice of U.S. wireless spectrum, and shares of AT&T, Verizon, and T-Mobile dropped within hours of the news. Elon Musk called the deal the last critical piece for complete phone coverage in America, fueling speculation about a future device that could challenge the iPhone.October 10 at 1:00 AM | Stansberry Research (Ad)SpyGlass Pharma Acquires Advanced Vision Science, Inc. (AVS), Securing Scalable Commercial IOL Supply and Accelerating Lens Portfolio Expansion CapabilityOctober 1, 2026 | globenewswire.comSpyglass Pharma, Inc. (NASDAQ:SGP) Stock Now Rated "Moderate Buy" by Wall Street AnalystsOctober 1, 2026 | americanbankingnews.comSpyGlass Pharma, Inc. (SGP) Presents at Citigroup's Biopharma Back to School Summit 2026 TranscriptSeptember 10, 2026 | seekingalpha.comSee More Spyglass Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Spyglass Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Spyglass Pharma and other key companies, straight to your email. Email Address About Spyglass PharmaSpyglass Pharma (NASDAQ:SGP) is a clinical-stage ophthalmic pharmaceutical company developing sustained-release drug-delivery technologies for the treatment of eye diseases. The company’s platform is designed to deliver medication inside the eye over extended periods, with the goal of reducing reliance on daily eye drops and improving treatment adherence. SpyGlass Pharma’s lead development programs focus on glaucoma and ocular hypertension, conditions in which elevated intraocular pressure can damage the optic nerve and lead to vision loss. Its portfolio includes intraocular implant candidates designed to provide controlled delivery of established ophthalmic medicines, including bimatoprost, over an extended period. The company conducts its research and clinical development activities primarily in the United States. SpyGlass Pharma is focused on advancing its implant-based therapies through clinical development and regulatory evaluation; detailed information about its broader commercial operations and leadership is limited.View Spyglass Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueMicrosoft Is Almost Back to $555—Now the Hard Part BeginsSkydance Just Became a Media Giant—With an $80 Billion Debt Load Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
